Breaking Finance News

Beaufort Securities retained Advanced Oncotherapy PLC (LON:AVO) to Speculative Buy in a statement released earlier today.

Boasting a price of 66.75GBX, Advanced Oncotherapy PLC (LON:AVO) traded -14.29% lower on the day. With the last stock price close down -50.48% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.03% over the date range. Advanced Oncotherapy PLC has recorded a 50-day average of 100.68GBX and a two hundred day average of 127.21GBX. Volume of trade was up over the average, with 425,360 shares of AVO changing hands over the typical 74,927

Beaufort Securities has retained Advanced Oncotherapy PLC (LON:AVO) to Speculative Buy in a statement released on Monday November 28, 2016.

Performance Chart

Advanced Oncotherapy PLC (LON:AVO)

With a total market value of 0 GBX, Advanced Oncotherapy PLC has with a 52 week low of 61.00GBX and a 52 week high of 217.25GBX .

General Information About Advanced Oncotherapy PLC (LON:AVO)

Advanced Oncotherapy Plc is focused on providing radiotherapy systems for cancer treatment through the use of a proton therapy technology. The Company is engaged in development and then building of the Linac Image Guided Hadron Technology (LIGHT) proton beam cancer therapy device and management of healthcare related property. The Company's segments include Development of Proton Therapy-UK; Development of Proton Therapy-Switzerland; Development of Proton Therapy-USA, and Healthcare-related properties-UK. Its LIGHT system uses accelerators, which is a series of modular units. This feature offers hospitals and centers to customize treatment plans based on a range of energies. The Company's Research and development/ADAM S.A. (R&D/ADAM) facility is located on the campus of European Council for Nuclear Research (CERN), Geneva, Switzerland, and a manufacturing plant, clinical research and clinician training facility in Syracuse, the United States.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *